Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

585.74 USD UNCHANGED
Streaming Delayed Price Updated: 7:59 PM EDT, Oct 26, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 585.74
Bid (Size) 574.14 (1)
Ask (Size) 588.00 (5)
Prev. Close 585.74
Today's Range 585.74 - 585.74
52wk Range 303.22 - 664.64
Shares Outstanding 105,949,824
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings
From GlobeNewswire News Releases
Dupixent® (dupilumab) Late-breaking Pivotal Data Showing Significant Improvement in Eosinophilic Esophagitis Signs and Symptoms Presented for the First Time at Scientific Meetings
From PR Newswire

Performance

YTD
+56.89%
+56.89%
1 Month
+2.42%
+2.42%
3 Month
-8.10%
-8.10%
6 Month
+6.98%
+6.98%
1 Year
+89.83%
+89.83%

More News

Read More
Are These The Best Biotech Stocks To Buy Before November 2020?
From Stockmarket.com
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
From GlobeNewswire News Releases
Scott+Scott Attorneys at Law LLP Continues to Investigate Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty (REGN)
From Business Wire News Releases
CHMP Recommends Approval of Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Severe Atopic Dermatitis
From PR Newswire
NIAID Study Finds Eli Lilly's Antibody Drug Unhelpful For Hospitalized COVID-19 Patients
Tags Market News the National Institute of Allergy and Infectious Diseases Bamlanivimab
From Benzinga
2nd Annual Gabelli Funds – Columbia Business School Healthcare Symposium (Virtual)
From Business Wire News Releases
Regeneron Pharmaceuticals Now #109 Largest Company, Surpassing Micron Technology
Tags Stocks
From Market News Video
Pfizer, Moderna Vaccines, Gilead Treatment In Focus As Health Firms Report Q3 Earnings
Tags AZN General Markets
From Benzinga
Market Briefing For Tuesday, Oct.27
Tags Stocks / Equities Consumer Goods Pharma/Biotech
From Blogs - TalkMarkets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.